RepliCel Life Sciences is a regenerative medicine company using cell therapy products for healing tendinosis, aging, and pattern baldness.
RepliCel Life Sciences has raised $224K in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2024.
RepliCel Life Sciences's investors include YOFOTO, MainPointe Pharmaceuticals.
RepliCel Life Sciences is headquartered in Vancouver, Canada.
RepliCel Life Sciences is a regenerative medicine company using cell therapy products for healing tendinosis, aging, and pattern baldness.
RepliCel Life Sciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RepliCel Life Sciences — Funding & Investors." VCBacked, December 16, 2024, https://www.vcbacked.co/company/replicel-life-sciences. Accessed November 12, 2026.
VCBacked. (2024). RepliCel Life Sciences — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/replicel-life-sciences
{{cite web |title=RepliCel Life Sciences — Funding & Investors |url=https://www.vcbacked.co/company/replicel-life-sciences |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at RepliCel Life Sciences? Request a listing update